This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Core Study: Change from Baseline in the CDR-SB at 18 Months
Timeframe: Baseline, 18 months
Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Timeframe: From first dose of study drug up to approximately 51 months (including 3 months follow up) for the extension phase
Extension Phase: Change from Core Study Baseline in CDR-SB
Timeframe: Baseline up to Month 66
Extension Phase Part B: Number of Participants Exposed to Lecanemab
Timeframe: From 48th month in extension phase part A to the end of extension phase part B (up to 24 months)